Article

More private payers to cover tibial nerve stimulation

Uroplasty, Inc. (Minneapolis) has announced that two additional private insurance payers will cover posterior tibial nerve stimulation (PTNS) using its Urgent PC Neuromodulation System for the treatment of overactive bladder and associated symptoms.

Uroplasty, Inc. (Minneapolis) has announced that two additional private insurance payers will cover posterior tibial nerve stimulation (PTNS) using its Urgent PC Neuromodulation System for the treatment of overactive bladder and associated symptoms.

Effective Aug. 1, 2011, Health Care Service Corp. will begin covering and paying for PTNS therapy for patients in Texas, Illinois, New Mexico, and Oklahoma. Additionally, effective May 18, 2011, BlueCross BlueShield of Nebraska initiated coverage of PTNS treatments.

"We have now secured coverage from three of the four largest private payers in the United States," said David Kaysen, president and CEO of Uroplasty. "We estimate that in total, the Medicare and private-pay carriers that today provide coverage for PTNS treatments represent approximately 115 million lives."

Related Videos
Landon Trost, MD, answers a question during a video interview
Jitesh Dhingra, MD, FRCEM, answers a question during a Zoom video interview
Oliver Sartor, MD, is featured in this series.
Ravi Munver, MD, answers a question during a Zoom video interview
1 KOL is featured in this series.
1 KOL is featured in this series.
Related Content
Man talking with doctor, who is taking notes on a clipboard | Image Credit: © DragonImages - stock.adobe.com
October 18th 2024

“Drain and retain” technique appears safe in IPP revision surgery

Benjamin P. Saylor
“In the absence of infection, [drain and retain] is a safe strategy without further complications compared to the primary groups," said Thairo Pereira, MD.
Key updates from the AUA/ASRM male infertility guideline amendment
September 23rd 2024

Key updates from the AUA/ASRM male infertility guideline amendment

Urology Times staff
In this episode, Robert E. Brannigan, MD, and Juan J. Andino, MD, MBA, discuss the recent amendment to the AUA/ASRM guideline on male infertility.
PACE-B trial: Five-fraction SBRT noninferior to conventional radiotherapy in prostate cancer
October 17th 2024

PACE-B trial: Five-fraction SBRT noninferior to conventional radiotherapy in prostate cancer

Hannah Clarke
At 5 years, 95.8% of patients in the SBRT arm were free from biochemical or clinical failure compared with 94.6% of patients in the control radiotherapy arm.
Speaking of Urology: Dr. Winter on the use of vaginal estrogen
July 24th 2024

Speaking of Urology: Dr. Winter on the use of vaginal estrogen

Urology Times staff
In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.
FDA accepts new drug application for UGN-102 in NMIBC
October 16th 2024

FDA accepts new drug application for UGN-102 in NMIBC

Hannah Clarke
The target action date for the application is June 13, 2025.
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
October 16th 2024

Is video-based research feasible for pediatric urology visits?

Francesca A. Williamson, PhD Pankaj P. Dangle, MD, MCh, FAAP
"This first paper was really to show that our research methodology was feasible and acceptable with pediatric urology patients and families. We've done that, and now we have a huge corpus of data that we can further analyze through empirical studies," says Francesca A. Williamson, PhD.
© 2024 MJH Life Sciences

All rights reserved.